The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer.
 
Hope Rugo
Consulting or Advisory Role - BioNTech; Bristol Meyer; Helsinn Therapeutics; Napo Pharmaceuticals
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Daiichi Sankyo (Inst); F. Hoffman-La Roche/Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Bernardo Rapoport
Consulting or Advisory Role - Acino Pharma South Africa; Astra-Zeneca South Africa; Janssen; MSD South Africa
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics; Zuellig Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Bliss Biopharmaceutical; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Relay Therapeutics; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Rita Nanda
Consulting or Advisory Role - Arvinas; AstraZeneca; Corcept Therapeutics; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Lilly; Mabwell; Merck; Novartis; Pfizer; Summit Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Mabwell Biosciences (Inst); Merck (Inst); OBI Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst)
Other Relationship - G1 Therapeutics
 
Sung-Bae Kim
Consulting or Advisory Role - AstraZeneca; BeiGene; BNT; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Genexine; Gilead Sciences; Lilly (Inst); Novartis; TiumBio
Travel, Accommodations, Expenses - Lilly
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
 
Chiun-Sheng Huang
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiich Sankyo; EirGenix; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Daiich Sankyo; Lilly; MSD; Novartis; Roche
Research Funding - Aston Sci (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer; Roche
 
Michelle Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Daiichi Sankyo/Astra Zeneca (I); Gilead Sciences (I)
Consulting or Advisory Role - Genentech
Research Funding - DAEHWA Pharmaceutical (Inst); Gilead Sciences (Inst); Lilly (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
Daphne Tsoi
No Relationships to Disclose
 
Claudio Rocha
No Relationships to Disclose
 
Zaida Morante
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST (Inst); Novartis (Inst)
 
Maricela Garcia Garces
Consulting or Advisory Role - Novartis
Speakers' Bureau - Amgen; MSD Oncology
Research Funding - Lilly; OBI Pharma
 
Dong Xu
Employment - OBI Pharma
Leadership - OBI Pharma
Stock and Other Ownership Interests - OBI Pharma
Travel, Accommodations, Expenses - OBI Pharma
 
Ingly Lee
Employment - OBI Pharma
 
Chu-Yun Chi
No Relationships to Disclose
 
Chia Chen
Employment - OBI Pharma
Leadership - OBI Pharma
Honoraria - OBI Pharma
Travel, Accommodations, Expenses - OBI Pharma